文献速递急性肾损伤

敲除IL-36受体通过减少促炎细胞因子减轻肾脏缺血再灌注损伤

Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines.
PubMed 文献 · Kidney Int · 2017-12-11

该研究利用双侧肾缺血再灌注损伤模型,对比IL-36R敲除与野生型小鼠,发现敲除IL-36R后血浆肌酐、尿素氮及IL-6水平显著降低,肾小管损伤减轻;体外实验显示IL-36α可上调NF-κB活性与Erk磷酸化;AKI患者尿IL-36α水平升高且肾活检IL-36α染色增强。提示IL-36α/IL-36R阻断可能成为AKI治疗靶点。

要点

  • IL-36R敲除减轻肾缺血再灌注损伤后的肾功能损害和肾小管损伤。
  • IL-36α/IL-36R轴可能通过NF-κB和Erk途径促进促炎细胞因子产生。
  • AKI患者尿IL-36α升高、肾组织IL-36α染色增强,提示其作为生物标志物潜力。

核心结论

  • IL-36α/IL-36R阻断可能是急性肾损伤的潜在治疗靶点。

研究设计与样本

  • 采用IL-36R敲除小鼠与野生型小鼠建立双侧肾缺血再灌注损伤模型。
  • 并进行原代肾小管上皮细胞培养实验及AKI患者样本分析。

主要发现

  • IL-36R敲除小鼠缺血再灌注后血浆肌酐、尿素氮和IL-6水平显著低于野生型小鼠。
  • IL-36R敲除小鼠肾组织免疫组化显示肾小管损伤较轻。
  • 缺血再灌注后IL-36α/β/γ水平升高,IL-36α表达于淋巴细胞和近端肾小管细胞。
  • IL-36R敲除小鼠缺血再灌注后IL-6和TNF-α mRNA水平较低。
  • 原代肾小管上皮细胞中IL-36α处理上调NF-κB活性和Erk磷酸化。

关键数值与推荐

  • AKI患者尿IL-36α水平升高,肾活检样本中IL-36α染色增强。

临床怎么用

  • 提示监测尿IL-36α可能有助于AKI的识别,但尚需进一步验证。
  • IL-36α/IL-36R轴作为治疗靶点仍需临床研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IL-36, a newly named member of the IL-1 cytokine family, includes 3 isoforms, IL-36α, IL-36β, and IL-36γ, all of which bind to a heterodimer containing the IL-36 receptor (IL-36R). Little is known about the role of the IL-36 axis in acute kidney injury (AKI) pathogenesis. Therefore, we evaluated IL-36 function in the bilateral renal ischemia-reperfusion injury model of AKI using IL-36R knockout and wild-type mice. IL-36R was found to be expressed in the kidney, mainly in proximal tubules. In IL-36R knockout mice, plasma creatinine, blood urea nitrogen, and IL-6 levels after ischemia-reperfusion injury were significantly lower than those in wild-type mice. Immunohistological analysis revealed mild tubular injury. IL-36α/β/γ levels were increased after ischemia-reperfusion injury, and IL-36α was expressed in lymphocytes and proximal tubular cells, but post-ischemia-reperfusion injury mRNA levels of IL-6 and TNF-α were low in IL-36R knockout mice. In primary cultures of renal tubular epithelial cells, IL-36α treatment upregulated NF-κB activity and Erk phosphorylation. Notably, in patients with AKI, urine IL-36α levels were increased, and IL-36α staining in renal biopsy samples was enhanced. Thus, IL-36α/IL-36R blockage could serve as a potential therapeutic target in AKI.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Nishikawa H, Taniguchi Y, Matsumoto T, et al. Knockout of the interleukin-36 receptor protects against renal ischemia-reperfusion injury by reduction of proinflammatory cytokines. Kidney Int. 2017. PMID: 29241623. doi:10.1016/j.kint.2017.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。